These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18928667)

  • 1. Low-grade serous ovarian cancer: a unique disease.
    Schmeler KM; Gershenson DM
    Curr Oncol Rep; 2008 Nov; 10(6):519-23. PubMed ID: 18928667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
    Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian High-Grade Serous Carcinoma: Assessing Pathology for Site of Origin, Staging and Post-neoadjuvant Chemotherapy Changes.
    Casey L; Singh N
    Surg Pathol Clin; 2019 Jun; 12(2):515-528. PubMed ID: 31097113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome.
    Hsu CY; Kurman RJ; Vang R; Wang TL; Baak J; Shih IeM
    Hum Pathol; 2005 Oct; 36(10):1049-54. PubMed ID: 16226103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
    Shen XX; Yu L; Bi R; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary.
    Wong KK; Gershenson D
    Dis Markers; 2007; 23(5-6):377-87. PubMed ID: 18057521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
    Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
    Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
    Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-grade serous carcinoma: molecular features and contemporary treatment strategies.
    Angarita AM; Cholakian D; Fader AN
    Expert Rev Anticancer Ther; 2015; 15(8):893-9. PubMed ID: 26040191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-grade serous tumors of ovary.
    Bell DA
    Int J Gynecol Pathol; 2014 Jul; 33(4):348-56. PubMed ID: 24901394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-grade Serous Neoplasia of the Female Genital Tract.
    Folkins AK; Longacre TA
    Surg Pathol Clin; 2019 Jun; 12(2):481-513. PubMed ID: 31097112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data.
    Vang R; Shih IeM; Salani R; Sugar E; Ayhan A; Kurman RJ
    Am J Surg Pathol; 2008 Nov; 32(11):1667-74. PubMed ID: 18769340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
    Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
    Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.
    Canet B; Pons C; Espinosa I; Prat J
    Hum Pathol; 2011 Jun; 42(6):833-9. PubMed ID: 21208644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential.
    Crispens MA; Bodurka D; Deavers M; Lu K; Silva EG; Gershenson DM
    Obstet Gynecol; 2002 Jan; 99(1):3-10. PubMed ID: 11777502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
    Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM
    Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.